Monopar Therapeutics 8-K

What Happened

• Monopar Therapeutics announced on June 30, 2026 (via an 8-K, Item 7.01) that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline). The company furnished the related press release as Exhibit 99.1 to the filing.

Key Details

• Filing date: June 30, 2026 (Form 8-K, Item 7.01, Regulation FD Disclosure).
• Designation granted by: U.S. Food and Drug Administration (FDA).
• Product: ALXN1840 (tiomolibdate choline) — granted Rare Pediatric Disease designation.
• Exhibits: Press release dated June 30, 2026 (Exhibit 99.1); Inline XBRL cover page tags included (Exhibit 104).

Why It Matters

• The FDA’s Rare Pediatric Disease designation is a regulatory milestone signaling that the therapy targets a rare disease in pediatric populations; it is a formal recognition rather than an approval.
• For investors, this is material news about Monopar’s development progress and regulatory status for ALXN1840, but the 8-K does not include clinical data, approval, or financial results.